CN105943549A - Film-forming and bacterium-resisting agent for treating onychomycosis and preparation process of agent - Google Patents
Film-forming and bacterium-resisting agent for treating onychomycosis and preparation process of agent Download PDFInfo
- Publication number
- CN105943549A CN105943549A CN201610308375.3A CN201610308375A CN105943549A CN 105943549 A CN105943549 A CN 105943549A CN 201610308375 A CN201610308375 A CN 201610308375A CN 105943549 A CN105943549 A CN 105943549A
- Authority
- CN
- China
- Prior art keywords
- agent
- ceftriaxone
- tinea unguium
- film forming
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a film-forming and bacterium-resisting agent for treating onychomycosis and a preparation process of the agent, and belongs to the field of medical antibacterial medicines. The film-forming and bacterium-resisting agent for treating onychomycosis consists of 2,4,4'-trichloro-2'-hydroxy diphenyl ether, chitosan, a solubilizer, organic acid and purified water. According to the film-forming and bacterium-resisting agent for treating the onychomycosis, bactericidal ingredients of the 2,4,4'-trichloro-2'-hydroxy diphenyl ether are mixed by virtue of a bio-activity film forming technology, so that the bio-activity of the film-forming and bacterium-resisting agent for treating the onychomycosis is multiplied, and the problem of fungi in nails is thoroughly solved, so that cross infection is effectively prevented and recurrence after recovery is avoided. The preparation process of the film-forming and bacterium-resisting agent for treating the onychomycosis comprises a step of mixing and uniformly stirring the 2,4,4'-trichloro-2'-hydroxy diphenyl ether, the chitosan, the solubilizer, the organic acid and the purified water. The process is simple, and the prepared film-forming and bacterium-resisting agent for treating the onychomycosis is high in contents of the 2,4,4'-trichloro-2'-hydroxy diphenyl ether and the chitosan, good in bactericidal effect and strong in film-forming viscosity.
Description
Technical field
The present invention relates in medical antibacterial medicine field, in particular to a kind of film forming Ceftriaxone
Tinea unguium agent and processing technology thereof.
Background technology
Tinea unguium is a kind of dermatosis commonly encountered diseases, frequently-occurring disease, and medical name is tinea unguium, its cause of disease
Being caused by fungal infection fingernail, be department of dermatologry pertinacious disease, infectiousness is strong.For clinical antifungal
Medicine is all invalid to treatment tinea unguium because of impermeable cutin.Primary treatments is hands in the past
Art removes finger nail many people and fears its pain and difficult, becomes many people's particularly youngsters the most tired
Angry.
Summary of the invention
It is an object of the invention to provide a kind of film forming Ceftriaxone tinea unguium agent, use biological activity
Film technique, the effect thoroughly solve fungus in fingernail, promoting new first to grow, effectively prevent phase
Infect mutually, the recurrence after healing can be avoided.
Another object of the present invention is to provide the making work of a kind of film forming Ceftriaxone tinea unguium agent
Skill, the film forming Ceftriaxone tinea unguium agent prepared by this technique is good to the therapeutic effect of tinea unguium,
The recurrence after healing can be avoided.
The present invention solves it and technical problem is that and realize by the following technical solutions.
A kind of film forming Ceftriaxone tinea unguium agent, it includes by mass percentage:
A kind of processing technology of film forming Ceftriaxone tinea unguium agent, comprising:
It is on the waiting list raw material by mass percentage:
Chloro-for 2,4,4'-tri-2'-dihydroxy diphenyl ether, chitosan, solubilizing agent and organic acid are added purification
Water mixing and stirring.
Film forming Ceftriaxone tinea unguium agent that the embodiment of the present invention provides and processing technology useful thereof
Effect is: biological activity film technique, with 2,4,4'-trichlorines are used in film forming Ceftriaxone tinea unguium agent
-2'-dihydroxy diphenyl ether and chitosan, solubilizing agent and organic acid are main carriers, by 2, and 4,4'-tri-
The sterilization component of chloro-2'-dihydroxy diphenyl ether merges, and makes the biological of film forming Ceftriaxone tinea unguium agent live
Property increase several times, improve the aqueous of tinea unguium fingernail and tinea unguium surrounding tissue at short notice
Amount, makes tinea unguium local temperature raise, vasodilation, thoroughly solves fungus in fingernail.Not only
So, film forming Ceftriaxone tinea unguium agent can also be effectively promoted the effect of new first growth, enters first
Plate deep layer, the substrate epithelium basal cell that rehabilitation is impaired, form new first and increase the antibacterial of new first
Ability, effectively prevents from mutually infecting, the recurrence after healing can be avoided.And the system of film forming Ceftriaxone tinea unguium agent
Make technique simple, by by 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers and chitosan, solubilizing agent and
Organic acid adds purified water mix and blend, makes in the film forming Ceftriaxone tinea unguium agent prepared 2,4,4'-tri-
The content of chloro-2'-dihydroxy diphenyl ether and chitosan is high, and bactericidal effect is good, and film forming viscosity is strong.
Detailed description of the invention
For making the purpose of the embodiment of the present invention, technical scheme and advantage clearer, below by right
Technical scheme in the embodiment of the present invention is clearly and completely described.In embodiment unreceipted
Actual conditions person, the condition advised according to normal condition or manufacturer is carried out.Agents useful for same or instrument
Device unreceipted production firm person, being can be by the commercially available conventional products bought and obtain.
Film forming Ceftriaxone tinea unguium agent and processing technology thereof to the embodiment of the present invention below is carried out
Illustrate.
A kind of film forming Ceftriaxone tinea unguium agent, it includes by mass percentage:
Specifically, 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers are white crystalline powder, are that one is killed
Microbial inoculum, its dissolubility: be slightly soluble in water, it is dissolved in acetone, ethanol, isopropanol, propylene glycol and four
In the multi-solvents such as chlorination carbon and the kinds of surface activating agent such as polysorbas20, Tween 80.
Solubilizing agent: the surfactant with solubilising power is referred to as solubilizing agent.Wherein, solubilising is
Refer to that insoluble drug, under the effect of surfactant, increases dissolubility in a solvent and formed molten
The process of liquid.
Surfactant refers to substantially to reduce the total of the compound of surface tension or interfacial tension
Claim.Including ionic surfactant and the big class of nonionic surfactant two, it it is liquid system
Important component part in agent, has the effects such as solubilising, emulsifying and moistening.Solubilizing agent is surface
The one of activating agent.
Due to 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers are slightly soluble in water, but are dissolved in kinds of surface and live
Property agent, solubilizing agent is the one of surfactant, the embodiment of the present invention by by 2,4,4'-trichlorines
-2'-dihydroxy diphenyl ether and solubilizing agent mixing, the interpolation of solubilizing agent makes the chloro-2'-hydroxyl of increase by 2,4,4'-tri-
Yl diphenyl ether dissolubility in purified water, improves in film forming Ceftriaxone tinea unguium agent 2,4,4'-
The content of three chloro-2'-dihydroxy diphenyl ethers, and Absorption increase.Thus the chloro-2'-of 2,4,4'-tri-can be made
Dihydroxy diphenyl ether plays therapeutical effect so that certain concentration arrives tissue site, it is possible to avoid because of
Long-term prescription and there is toxic and side effects, effect is more preferable.
In the embodiment of the present invention, solubilizing agent is selected from Sodium Dimethyl Isophthalate-5-sulfonate or 12
Alkyl sodium sulfate.
Sodium Dimethyl Isophthalate-5-sulfonate is white powder stable under normal temperature and pressure, can
As solubilizing agent.Sodium lauryl sulphate is white or faint yellow powdery, is dissolved in water, to alkali and
Hard water is insensitive, is a kind of nontoxic anion solubilizing agent.
Solubilizing agent is selected from Sodium Dimethyl Isophthalate-5-sulfonate or sodium lauryl sulphate.Between
Dimethyl phthalate-5-sodium sulfonate and sodium lauryl sulphate are solubilizing agent, it is possible to strengthen
2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers dissolubility in purified water, improves film forming Ceftriaxone ash and refers to
The content of 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers in first agent, makes film forming Ceftriaxone tinea unguium agent
Bactericidal effect is more preferable.
Chitosan, by as film former, can form the thin film of layer of transparent, and shell on fingernail
Polysaccharide has preferable antibacterial activity, and the growth that can suppress some funguses, antibacterial and virus is numerous
Grow.Chitosan can not be dissolved completely in water and aqueous slkali, but dissolves in diluted acid.
In the embodiment of the present invention, organic acid can strengthen chitosan dissolubility in purified water,
Strengthen the content of chitosan in purified water.Organic acid is selected from glacial acetic acid or formic acid.Glacial acetic acid or first
Chitosan all can be preferably dissolved in acid, and after utilizing glacial acetic acid or formic acid to dissolve chitosan, shell
The viscosity of polysaccharide is good, it is simple to the molding of film.
Preferably, film forming Ceftriaxone tinea unguium agent in the embodiment of the present invention, by mass percentage,
Including:
Wherein, solubilizing agent is Sodium Dimethyl Isophthalate-5-sulfonate, and organic acid is glacial acetic acid.
In the embodiment of the present invention, select Sodium Dimethyl Isophthalate-5-sulfonate as solubilizing agent,
For dissolving 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ether；Select glacial acetic acid as organic acid, be used for
Dissolving chitosan, glacial acetic acid not only can dissolve chitosan, but also have certain sterilization
Effect, after chitosan film forming, glacial acetic acid can ceaselessly penetrate into fingernail root, kills disease
Bacterium, repairs fingernail regeneration.
The embodiment of the present invention uses biological activity film technique, with 2,4,4'-tri-chloro-2'-hydroxyls two
Phenylate and chitosan, solubilizing agent and organic acid are main carriers, by 2, and 4,4'-tri-chloro-2'-hydroxyls
The sterilization component of diphenyl ether merges, and makes the biological activity of film forming Ceftriaxone tinea unguium agent increase number
Times, improve tinea unguium fingernail and the water content of tinea unguium surrounding tissue at short notice, make ash refer to
First local temperature raises, vasodilation, thoroughly solves fungus in fingernail.Moreover, film forming
Ceftriaxone tinea unguium agent can also be effectively promoted the effect of new first growth, enters deck deep layer, health
Multiple impaired substrate epithelium basal cell, forms new first and increases the antibacterial ability of new first, effectively
Prevent from mutually infecting, the recurrence after healing can be avoided.
The bacteriostasis rate of the film forming Ceftriaxone tinea unguium agent that the embodiment of the present invention provides is 88～100%.
It is applied in the affected part of tinea unguium, it is possible to effectively prevent from mutually infecting, the recurrence after healing can be avoided.
A kind of processing technology of film forming Ceftriaxone tinea unguium agent, comprising:
It is on the waiting list raw material by mass percentage:
Chloro-for 2,4,4'-tri-2'-dihydroxy diphenyl ether, chitosan, solubilizing agent and organic acid are added purification
Water mixing and stirring.
Specifically, by 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers and solubilizing agent are mixed and added into part
Purified water, under condition of water bath heating, stir to clarify transparent first solution of making, wherein,
The heating-up temperature of heating in water bath is 60～80 DEG C；Chitosan and organic acid are mixed and added into residue
Purified water, under condition of water bath heating, stir to clarify transparent second solution of making, wherein,
The heating-up temperature of heating in water bath is 50～70 DEG C；And the first solution and the second solution are mixed,
Stir.Then the first solution and the mixed liquor of the second solution are filtered, and after standing 2～3 days,
Take supernatant.
First by 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers mix with solubilizing agent, it is simple to 2,4,4'-tri-chloro-2'-
Dihydroxy diphenyl ether is dissolved in purified water；In like manner, chitosan and organic acid are mixed, it is simple to shell gathers
After sugar and organic acid reaction, it is dissolved in purified water, and the viscosity of chitosan increases, then at two
Solution mixes, and dissolves rapider.In the present embodiment, by 2,4,4'-tri-chloro-2'-hydroxyl hexichol
When ether mixes with solubilizing agent and chitosan and organic acid mixed, all use heating in water bath, temperature
Raise and be conducive to improving 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ether and the dissolution velocity of solubilizing agent and molten
Xie Du, in like manner, chitosan and organic acid are when mixing, and it is molten that temperature rising is also beneficial to promote it
Solve speed and dissolubility, shorten the response time.
The using method of the film forming Ceftriaxone tinea unguium agent that the embodiment of the present invention provides:
Use every day 2～3 times, the film forming Ceftriaxone the ash the most continuously embodiment of the present invention provided
Fingernail agent is applied in tinea unguium, after fingernail is dry, repastes once, continuous 4～5 times, is again coated with
Used time, can first remove the biomembrane of residual at tinea unguium, then be coated with according still further to said method
With.
Biological activity film technique, with 2,4,4'-tri-chloro-2'-are used in film forming Ceftriaxone tinea unguium agent
Dihydroxy diphenyl ether and chitosan, solubilizing agent and organic acid are main carriers, by 2, and 4,4'-tri-chloro-2'-
The sterilization component of dihydroxy diphenyl ether merges, and makes the biological activity of film forming Ceftriaxone tinea unguium agent increase
Several times, improve tinea unguium fingernail and the water content of tinea unguium surrounding tissue at short notice, make ash
Nail topical temperature raises, vasodilation, thoroughly solves fungus in fingernail.Moreover, become
Film Ceftriaxone tinea unguium agent can also be effectively promoted the effect of new first growth, enters deck deep layer,
The substrate epithelium basal cell that rehabilitation is impaired, forms new first and increases the antibacterial ability of new first, having
Effect prevents from mutually infecting, and the recurrence after healing can be avoided.
Embodiment one
It is on the waiting list raw material:
Chloro-for 2,4,4'-tri-2'-dihydroxy diphenyl ether and sodium lauryl sulphate are mixed and added into part
Purified water, under condition of water bath heating, stir to clarify transparent first solution of making, wherein,
The heating-up temperature of heating in water bath is 60 DEG C；Chitosan and formic acid are mixed and added into remaining pure
Change water, stir to clarify under condition of water bath heating and transparent make the second solution, wherein, water-bath
The heating-up temperature of heating is 50 DEG C；Then the first solution and the second solution being mixed, stirring is all
Even.Then filter the first solution and the mixed liquor of the second solution, and after standing 2～3 days, take
Clear liquid.
Embodiment two
It is on the waiting list raw material:
Chloro-for 2,4,4'-tri-2'-dihydroxy diphenyl ether and sodium lauryl sulphate are mixed and added into part
Purified water, under condition of water bath heating, stir to clarify transparent first solution of making, wherein,
The heating-up temperature of heating in water bath is 65 DEG C；Chitosan and glacial acetic acid are mixed and added into remaining
Purified water, stirs to clarify under condition of water bath heating and transparent makes the second solution, wherein, water
The heating-up temperature of bath heating is 55 DEG C；Then the first solution and the second solution are mixed, stirring
Uniformly.Then filter the first solution and the mixed liquor of the second solution, and after standing 2～3 days, take
Supernatant.
Embodiment three
It is on the waiting list raw material:
Chloro-for 2,4,4'-tri-2'-dihydroxy diphenyl ether is mixed also with dimethyl phthalate-5-sodium sulfonate
Add the purified water of part, under condition of water bath heating, stir to clarify that transparent to make first molten
Liquid, wherein, the heating-up temperature of heating in water bath is 70 DEG C；Chitosan and glacial acetic acid are mixed also
Add remaining purified water, under condition of water bath heating, stir to clarify that transparent to make second molten
Liquid, wherein, the heating-up temperature of heating in water bath is 60 DEG C；Then by molten to the first solution and second
Liquid mixes, and stirs.Then filter the first solution and the mixed liquor of the second solution, and stand
After 2 days, take supernatant.
Embodiment four
It is on the waiting list raw material:
Chloro-for 2,4,4'-tri-2'-dihydroxy diphenyl ether is mixed also with dimethyl phthalate-5-sodium sulfonate
Add the purified water of part, under condition of water bath heating, stir to clarify that transparent to make first molten
Liquid, wherein, the heating-up temperature of heating in water bath is 60 DEG C；Chitosan and glacial acetic acid are mixed also
Add remaining purified water, under condition of water bath heating, stir to clarify that transparent to make second molten
Liquid, wherein, the heating-up temperature of heating in water bath is 50 DEG C；Then by molten to the first solution and second
Liquid mixes, and stirs.Then filter the first solution and the mixed liquor of the second solution, and stand
After 3 days, take supernatant.
Embodiment five
It is on the waiting list raw material:
Chloro-for 2,4,4'-tri-2'-dihydroxy diphenyl ether is mixed also with dimethyl phthalate-5-sodium sulfonate
Add the purified water of part, under condition of water bath heating, stir to clarify that transparent to make first molten
Liquid, wherein, the heating-up temperature of heating in water bath is 80 DEG C；Chitosan and glacial acetic acid are mixed also
Add remaining purified water, under condition of water bath heating, stir to clarify that transparent to make second molten
Liquid, wherein, the heating-up temperature of heating in water bath is 70 DEG C；Then by molten to the first solution and second
Liquid mixes, and stirs.Then filter the first solution and the mixed liquor of the second solution, and stand
After 3 days, take supernatant.
The embodiment of the present invention will make the treatment of a course for the treatment of for tinea unguium patient, and normal with market
Rule medicine compares, and draws analysis result.It is below specifying information:
Patient data: choose my institute and accept patient for medical treatment and be diagnosed as patient 50 example of tinea unguium, age
23～50 years old, it is divided into treatment group and matched group at random, two groups of patients are in age, the course of disease, palace
The indexing of neck erosion and type etc. are without significant difference.Wherein treatment group uses the embodiment of the present invention
The film forming Ceftriaxone tinea unguium agent provided；Matched group uses the medicine for external use of conventional therapy tinea unguium
Agent: the iodine tincture of 15%.
Tinea unguium has six kinds of Clinical types:
1, far-end first mo(u)ld bottom half: pathogenic bacterium first invade far-end deck and nail matrix.Infected deck
Tarnish and the transparency, thicken, in canescence, taupe or turbid yellow.The easy brittle failure in deck,
Surface relief is uneven；Also can deck, nail matrix separate, pile up some keratosa squamas under first.
2, near-end first mo(u)ld bottom half: candidal paronychia is often from the beginning of nail groove near-end or first side pleat
Occurring, later pathogenic bacterium invade near-end deck, occur white, green at deck near-end and side
Or black changes, gradually invading deck far-end, deck becomes muddiness, traverse furrow, vertical ridge or point occurs
Shape caves in, and deck becomes fragile and separates with nail matrix.
3, shallow vindication A type: pathogenic bacterium directly invade top layer, deck, from the beginning of time be less than 1mm
White island shape, flaring be fused into greatly white haze, deck surface uneven or
Deformation.
4, deck inner mold: pathogenic bacterium pass horny zone of nail, forms off-white color patch, without under first
Hyperkeratosis or first separate.Fungal mycelia is also had to form agglomerate, referred to as first fungosity in first.
5, tinea unguium under black first: by first far-end, spread to full first, black, deck
Thicken.
6, full first damage type: be the final final result of all kinds tinea unguium development, fungus invades
Whole deck, first architecture lost: nail matrix and nail matrix are that papillary tumor sample changes, its overlying
Cover irregular keratinization agglomerate.
Treatment group and matched group all include the patient of above-mentioned six types.
Diagnostic criteria: new first grows completely.
Using method:
Treatment group: use every day three times, resists the film forming that the embodiment of the present invention provides the most continuously
Bacterium is controlled tinea unguium agent and is applied in tinea unguium, after fingernail is dry, repastes one layer, continuous 4～5 layers,
Again it is coated with the used time, can first remove the biomembrane of residual at tinea unguium, then according still further to said method
Carry out being coated with and use.
Matched group: use every day three times, is coated in tinea unguium affected part with the iodine solution point of 10%.
After using 1 month continuously, do further consultation for the first time, after drug withdrawal 30 days, do second time multiple
Examine, and contrast with first time further consultation situation.
Therapeutic outcome sees table 1.
Table 1. treatment group and matched group efficacy result
| Group | Number of cases | Recovery from illness | Effective | Effectively | Invalid | Recurrence | Cure rate % | Total effective rate % | Relapse rate % |
| Treatment group | 25 | 20 | 3 | 2 | 0 | 0 | 80 | 100 | 0 |
| Matched group | 25 | 10 | 5 | 4 | 6 | 8 | 40 | 80 | 32 |
The film forming Ceftriaxone tinea unguium agent that the embodiment of the present invention provides is to various types of tinea unguium
The most effective in cure, treatment time is short, and therapeutic effect is good.Take the film forming that the embodiment of the present invention provides
25 examples of Ceftriaxone tinea unguium agent, after using 1 month, new first grows, and recovery effects is good.
Total effective rate is 100%.
And in reference examples, although the iodine solution of 10% has certain therapeutic effect to tinea unguium,
But weak curative effect, and easily recur.
In above-mentioned 50 examples, have no side effect and anaphylactoid generation, safely, effectively.Use
After one month, tinea unguium is significantly improved.For the patient not fully recovered, adhere to making
After 2 months, can fully recover, and be not easy recurrence.
The embodiment of the present invention also conventional treatments and becoming that the present embodiment provides to tinea unguium
Film Ceftriaxone tinea unguium agent contrasts.
Concrete data see table 2.
Table 2. conventional treatments and the Comparison of therapeutic of film forming Ceftriaxone tinea unguium agent
The film forming Ceftriaxone tinea unguium agent that the embodiment of the present invention provides is compared to conventional tinea unguium
Therapeutic effect is notable, hurtless measure, has no side effect and film forming Ceftriaxone tinea unguium agent can be deep enough
Sick first and deck compacted zone, thoroughly kill fungus, good effect, is difficult to recurrence.
Embodiments described above is a part of embodiment of the present invention rather than whole enforcement
Example.The detailed description of embodiments of the invention is not intended to limit the model of claimed invention
Enclose, but be merely representative of the selected embodiment of the present invention.Based on the embodiment in the present invention, this
It is every other that field those of ordinary skill is obtained under not making creative work premise
Embodiment, broadly falls into the scope of protection of the invention.
Claims (10)
1. a film forming Ceftriaxone tinea unguium agent, it is characterised in that it is by mass percentage
Meter includes:
Film forming Ceftriaxone tinea unguium agent the most according to claim 1, it is characterised in that
Described solubilizing agent is selected from Sodium Dimethyl Isophthalate-5-sulfonate or sodium lauryl sulphate.
Film forming Ceftriaxone tinea unguium agent the most according to claim 1, it is characterised in that
Described organic acid is selected from glacial acetic acid or formic acid.
Film forming Ceftriaxone tinea unguium agent the most according to claim 1, it is characterised in that
By mass percentage, including
Wherein, described solubilizing agent is Sodium Dimethyl Isophthalate-5-sulfonate, described organic acid
For glacial acetic acid.
Film forming Ceftriaxone tinea unguium agent the most according to claim 1, it is characterised in that
The bacteriostasis rate of described film forming Ceftriaxone tinea unguium agent is 88～100%.
6. the processing technology of a film forming Ceftriaxone tinea unguium agent, it is characterised in that its bag
Include:
It is on the waiting list raw material by mass percentage:
By described 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ether, described chitosan, described solubilizing agent and institute
State organic acid and add described purified water mixing and stirring.
The processing technology of film forming Ceftriaxone tinea unguium agent the most according to claim 6,
It is characterized in that, by described 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ethers, described chitosan, described
Solubilizing agent, described organic acid add the mixing of described purified water and include:
Described 2,4,4'-tri-chloro-2'-dihydroxy diphenyl ether and described solubilizing agent are mixed and added into part
Described purified water stir to clarify and transparent make the first solution；
Described chitosan and described organic acid are mixed and added into the stirring of remaining described purified water
The second solution is made to clear；And
By described first solution and described second solution mixing, stir.
The processing technology of film forming Ceftriaxone tinea unguium agent the most according to claim 7,
It is characterized in that, when making described first solution, heating in water bath, heating-up temperature is
60～80 DEG C.
The processing technology of film forming Ceftriaxone tinea unguium agent the most according to claim 7,
It is characterized in that, when making described second solution, heating in water bath, heating-up temperature is
50～70 DEG C.
The processing technology of film forming Ceftriaxone tinea unguium agent the most according to claim 7,
It is characterized in that, after by described first solution and described second solution mix and blend, filter also
After standing 2～3 days, take supernatant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610308375.3A CN105943549A (en) | 2016-05-10 | 2016-05-10 | Film-forming and bacterium-resisting agent for treating onychomycosis and preparation process of agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610308375.3A CN105943549A (en) | 2016-05-10 | 2016-05-10 | Film-forming and bacterium-resisting agent for treating onychomycosis and preparation process of agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105943549A true CN105943549A (en) | 2016-09-21 |
Family
ID=56911222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610308375.3A Pending CN105943549A (en) | 2016-05-10 | 2016-05-10 | Film-forming and bacterium-resisting agent for treating onychomycosis and preparation process of agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105943549A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1449273A (en) * | 2000-07-24 | 2003-10-15 | 波利凯姆有限公司 | Antimicotic nail varnish composition |
| CN1457764A (en) * | 2003-06-10 | 2003-11-26 | 汪瑜 | Liquid composition and its preparing method and use |
| CN101491537A (en) * | 2008-01-24 | 2009-07-29 | 程斌 | Glacial acetic acid chitosan composite antibiotic liquid |
| CN101584863A (en) * | 2009-03-03 | 2009-11-25 | 胡长有 | Medicament for external use for treating onychomycosis |
-
2016
- 2016-05-10 CN CN201610308375.3A patent/CN105943549A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1449273A (en) * | 2000-07-24 | 2003-10-15 | 波利凯姆有限公司 | Antimicotic nail varnish composition |
| CN1457764A (en) * | 2003-06-10 | 2003-11-26 | 汪瑜 | Liquid composition and its preparing method and use |
| CN101491537A (en) * | 2008-01-24 | 2009-07-29 | 程斌 | Glacial acetic acid chitosan composite antibiotic liquid |
| CN101584863A (en) * | 2009-03-03 | 2009-11-25 | 胡长有 | Medicament for external use for treating onychomycosis |
Non-Patent Citations (3)
| Title |
|---|
| 冯延民: "《壳聚糖与人类健康》", 31 March 2008 * |
| 曲剑华: "《美容中医科》", 30 April 2014 * |
| 曾庆孝等: "《食品加工与保藏原理 第2版》", 31 August 2007 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105816908B (en) | Waterproof liquid wound protection film and preparation method thereof | |
| CN100998575B (en) | Finger nail coating agent of antifungal agent and its preparing method | |
| CN100457084C (en) | Nanometer silver type external use antibiotic gel for female external use and its prepn. method | |
| CN103127140B (en) | Compound external use drug curing psoriasis | |
| CN107233419A (en) | A kind of infantile eczema cream and preparation method thereof | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| AYRES et al. | Recurrent herpetiform dermatitis repens | |
| CN102302510B (en) | Medicinal composition and application thereof | |
| CN104888058B (en) | A kind of antibacterial, anti-inflammatory external preparation and preparation method thereof | |
| CN104042640A (en) | Nasal spray of seaweed extract and preparation method thereof | |
| CN106266597A (en) | A kind of Abelmoschus manihot （L.） Medic Bletilla glucomannan spray-filming agent and preparation method thereof | |
| CN103239586A (en) | Flavored agastache turbidity-dispelling external preparation as well as preparation method and application thereof | |
| CN105943549A (en) | Film-forming and bacterium-resisting agent for treating onychomycosis and preparation process of agent | |
| CN101829178A (en) | Medicine composition for treating diaper rash and preparation method thereof | |
| CN105030818B (en) | A kind of I types povidone iodine gargle and its preparing process | |
| CN108653304A (en) | A kind of pterostilbene nano-micelle external-use gel and preparation method thereof | |
| CN103157071B (en) | Chinese herbal compound film for treating dermatomycosis and preparation method thereof | |
| CN108938703A (en) | The gynecological gel of quick antibacterial | |
| CN104887623B (en) | A kind of II types povidone iodine gargle | |
| CN107115377A (en) | A kind of kuh-seng medicinal liquor and preparation method thereof | |
| CN104306436B (en) | A kind of Quick itch stopping sterilized articles therefrom | |
| CN107412647A (en) | A kind of external preparation for the antipruritic lasting that sterilizes | |
| CN108066278A (en) | A kind of gynaecology's gel containing chitosan oligosaccharide and preparation method thereof | |
| CN1257733C (en) | Skin and mueosa tissue disinfectant and its processing method | |
| CN110772501A (en) | Headache pain relieving plaster and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |
|
| RJ01 | Rejection of invention patent application after publication |